Effect of different injection times of platelet-rich plasma on knee osteoarthritis

doi:10.3877/cma.j.issn.1674-134X.2022.03.002

Abstract

Abstract:

Objective

To explore the effect of different injection frequencies of PRP on the efficacy of knee osteoarthritis.

Methods

A total of 90 patients with knee osteoarthritis in Henan Provincial People's Hospital from February 2018 to February 2019 were included in the study. Inclusion criteria: the patient met the diagnostic criteria of knee osteoarthritis, the duration of the disease were more than four months, and the X-ray Kellgren-Lawrence classification (K-L grading) were grade Ⅱ-Ⅲ. Exclusion criteria: patients with rheumatoid arthritis, recent knee trauma or surgical history, gout, blood diseases, tumors and other diseases. According to the frequency of injection, they were randomly divided into the one-time group, three-time group and five-time group, 30 patients in each group receiving one, three and five times PRP injection respectively, once a week. The knee joint function was assessed by visual analogue pain scale (VAS) and Western Ontario and McMaster University osteoarthritis index (WOMAC) before the treatment, and six, 12, 24 weeks after the treatment, and the knee joint cartilage status was assessed by ultrasonic semi-quantitative grading. VAS score and WOMAC score were evaluated by repeated measure ANOVA, paired sample t test was used before and after treatment in ultrasound semi-quantitative evaluation within the group, and one-way ANOVA was used for comparison between groups.

Results

At six weeks after the treatment, VAS score and WOMAC score in the three-and five-time groups were significantly lower than those in the one-time group (F =17.922, 22.215, both P<0.01). In 12 weeks after the treatment, VAS score and WOMAC score in the three-and five-time groups were significantly lower than those in the one-time group (F=71.058, 39.592, both P<0.01). In 24 weeks after the treatment, VAS score, WOMAC score and ultrasonic semi-quantitative score in the three- and five-time groups were significantly lower than those in the one-time group (F=163.974, 86.980, 6.781, all P<0.01).

Conclusion

The efficacy of three and five injections of PRP is better than one injection of PRP, but there is no obvious difference between three and five injections.

Key words: Osteoarthritis, Knee, Platelet-rich plasma, Injections, Ultrasonography

Wanyue Li, Yaru Shang, Weisheng Zhuang, Baoyan Qian, Ying Zhang, Xiaolin Wang. Effect of different injection times of platelet-rich plasma on knee osteoarthritis[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2022, 16(03): 267-272.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2022.03.002

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2022/V16/I03/267

Figures/Tables 5

References 20

[1]	Hawker GA, Croxford R, Bierman AS, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population based cohort study[J/OL]. PLoS One, 2014, 9(3): e91286. DOI：10.1016/j.joca.2014.02.089.
[2]	Rehart S, Wickler B, Nitschmann S. Osteoarthritis of the knee: physical therapy or intra-articular corticoid injection[J]. Internist (Berl), 2020, 61(10): 1087-1090.
[3]	李川，卜鹏飞，韩云峰，等．运动治疗膝骨关节炎的实施方案及临床探索[J/CD]．中华关节外科杂志(电子版)，2021，15(1)：98-103.
[4]	Cole BJ, Seroyer ST, Filardo G, et al. Platelet-rich plasma: where are we now and where are we going？[J]. Sports Health, 2010, 2(3): 203-210.
[5]	邢丹，余楠生，袁霆，等．关节腔注射富血小板血浆治疗膝骨关节炎的临床实践指南(2018年版)[J/CD]．中华关节外科杂志(电子版)，2018，12(4)：444-448.
[6]	Görmeli G, Görmeli CA, Ataoglu B, et al. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: a randomized, double-blind, placebo-controlled trial[J]. Knee Surg Sports Traumatol Arthrosc, 2017, 25(3): 958-965.
[7]	Patel S, Dhillon MS, Aggarwal S, et al. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial[J]. Am J Sports Med, 2013, 41(2): 356-364.
[8]	Kavadar G, Demircioglu DT, Celik MY, et al. Effectiveness of platelet-rich plasma in the treatment of moderate knee osteoarthritis: a randomized prospective study[J]. J Phys Ther Sci, 2015, 27(12): 3863-3867.
[9]	中华医学会骨科学分会关节外科学组．骨关节炎诊疗指南(2018年版)[J]．中华骨科杂志，2018，38(12)：705-715.
[10]	袁霆，张长青．骨组织及软组织修复作用中富血小板血浆的制作及其原理[J]．中国临床康复，2004，8(35)：7939-7941.
[11]	Mohammad S, Rik K. Platelet-rich plasma (PRP) for knee disorders[J]. Efort Open Reviews, 2017, 2(2)：28-34.
[12]	Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease[J]. Hypertension, 2004, 44(2): 203-209.
[13]	王新刚，黄鹏，雷玉凯．超声半定量评估膝关节软骨退变程度与临床表现的相关性分析[J]．中国实验诊断学，2020，24(2)：272-274.
[14]	Jevsevar DS. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition[J]. J Am Acad Orthop Surg, 2013, 21(9): 571-576.
[15]	Van Buul GM, Koevoet WL, Kops N, et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes[J]. Am J Sports Med, 2011, 39(11): 2362-2370.
[16]	Mccarrel T, Fortier L. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression[J]. J Orthop Res, 2009, 27(8): 1033-1042.
[17]	Song S, Cha YD, Han J, et al. Hyaline cartilage regeneration using mixed human chondrocytes and transforming growth factor-beta1- producing chondrocytes[J]. Tissue Eng, 2005, 11(9/10): 1516-1526.
[18]	Chen C, Chen JL, Hsu CC, et al. Injecting autologous platelet rich plasma solely into the knee joint is not adequate in treating geriatric patients with moderate to severe knee osteoarthritis[J]. Exp Gerontol, 2019, 119(5): 1-6.
[19]	齐清华，刘宏建，赵艳萍，等．彩色超微血管成像技术及高频超声在早期幼年特发性关节炎膝关节病变的应用[J]．中华实验外科杂志，2018，35(12)：2330-2332.
[20]	温朝美．肌骨超声评分系统在类风湿关节炎中的应用[J]．中国医学影像技术，2016，32(5)：807-810.

组别	例数	性别[例(%)]		年龄[岁，(±s)]	病程[年，(±s)]	初始血小板浓度[10⁹个/L，(±s)]	BMI[ kg/m²，(±s)]
组别	例数	男	女	年龄[岁，(±s)]	病程[年，(±s)]	初始血小板浓度[10⁹个/L，(±s)]	BMI[ kg/m²，(±s)]
1次组	27	9(33.3)	18(66.7)	59.7±6.3	4.8±2.6	208.6±32.1	27.1±1.1
3次组	28	8(28.6)	20(71.4)	60.9±5.4	4.9±2.5	209.3±33.0	27.6±1.5
5次组	28	10(35.7)	18(64.3)	60.7±5.5	4.8±1.9	206.7±27.7	27.7±1.3
统计值		χ²＝0.337		F＝0.333	F＝0.022	F＝0.051	F＝1.496
P值		>0.05		>0.05	>0.05	>0.05	>0.05

组别	例数	性别[例(%)]		年龄[岁，(±s)]	病程[年，(±s)]	初始血小板浓度[10⁹个/L，(±s)]	BMI[ kg/m²，(±s)]
组别	例数	男	女	年龄[岁，(±s)]	病程[年，(±s)]	初始血小板浓度[10⁹个/L，(±s)]	BMI[ kg/m²，(±s)]
1次组	27	9(33.3)	18(66.7)	59.7±6.3	4.8±2.6	208.6±32.1	27.1±1.1
3次组	28	8(28.6)	20(71.4)	60.9±5.4	4.9±2.5	209.3±33.0	27.6±1.5
5次组	28	10(35.7)	18(64.3)	60.7±5.5	4.8±1.9	206.7±27.7	27.7±1.3
统计值		χ²＝0.337		F＝0.333	F＝0.022	F＝0.051	F＝1.496
P值		>0.05		>0.05	>0.05	>0.05	>0.05

组别	例数	治疗前	治疗后6周	治疗后12周	治疗后24周	F值	P值
1次组	27	6.7±0.9	3.5±0.8^a	4.3±0.9^a	5.3±0.9^a	239.696	<0.001
3次组	28	6.7±0.9	2.3±0.8^ab	2.2±0.7^ab	2.1±0.8^ab	592.563	<0.001
5次组	28	6.7±0.8	2.1±1.1^ab	1.8±0.8^ab	1.8±0.6^ab	681.948	<0.001
F值		0.001	17.922	71.058	163.974	1 260.85	<0.001^c
P值		>0.05	<0.001	<0.001	<0.001	49.091	<0.001^d
						20.056	0.003^e

组别	例数	治疗前	治疗后6周	治疗后12周	治疗后24周	F值	P值
1次组	27	6.7±0.9	3.5±0.8^a	4.3±0.9^a	5.3±0.9^a	239.696	<0.001
3次组	28	6.7±0.9	2.3±0.8^ab	2.2±0.7^ab	2.1±0.8^ab	592.563	<0.001
5次组	28	6.7±0.8	2.1±1.1^ab	1.8±0.8^ab	1.8±0.6^ab	681.948	<0.001
F值		0.001	17.922	71.058	163.974	1 260.85	<0.001^c
P值		>0.05	<0.001	<0.001	<0.001	49.091	<0.001^d
						20.056	0.003^e

组别	例数	治疗前	治疗后6周	治疗后12周	治疗后24周	F值	P值
1次组	27	160±27	106±17^a	113±17^a	142±29^a	135.450	<0.001
3次组	28	171±19	83±20^ab	81±19^ab	80±18^ab	590.078	<0.001
5次组	28	170±15	74±19^ab	71±18^ab	69±17^ab	565.488	<0.001
F值		2.282	22.215	39.592	86.980	502.315	<0.001^c
P值		0.109	<0.001	<0.001	<0.001	27.845	<0.001^d
						20.009	<0.001^e

Please choose a citation manager

Content to export